🔗 Visit the ClinicalTrials.gov page for NCT00131274
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. | Am J Respir Crit Care Med | 2009 | 2.63 |
| 2 | Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. | Cancer Res | 2009 | 1.20 |
| 3 | A review of current and novel therapies for idiopathic pulmonary fibrosis. | J Thorac Dis | 2013 | 1.18 |
| 4 | New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. | Am J Respir Crit Care Med | 2014 | 1.02 |
| 5 | Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta. | Dev Cell | 2009 | 0.95 |
| 6 | Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. | Nat Rev Drug Discov | 2015 | 0.93 |
| 7 | Innovative approaches to the therapy of fibrosis. | Curr Opin Rheumatol | 2009 | 0.88 |
| 8 | Treatment of COPD: a matrix perspective. | Int J Chron Obstruct Pulmon Dis | 2008 | 0.83 |